TY - JOUR
T1 - Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis
AU - Smith, Miriam J
AU - Perez-Becerril, Cristina
AU - van der Meer, Mwee
AU - Burghel, George J
AU - Waller, Sarah J
AU - Carney, Megan
AU - Bunstone, Sancha
AU - Fryer, Katherine
AU - Bowers, Naomi L
AU - Hartley, Claire L
AU - Smith, Philip T
AU - Rutherford, Scott A
AU - Freeman, Simon R
AU - Lloyd, Simon K W
AU - Pathmanaban, Omar N
AU - King, Andrew Thomas
AU - Halliday, Dorothy
AU - Duff, Chris
AU - Evans, D Gareth
N1 - © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2024/10/23
Y1 - 2024/10/23
N2 - BACKGROUND: Most schwannomas are isolated tumours occurring in otherwise healthy people. However, bilateral vestibular schwannomas (BVS) or multiple non-vestibular schwannomas indicate an underlying genetic predisposition. This is most commonly
NF2-related schwannomatosis (SWN), but when BVS are absent, this can also indicate
SMARCB1-related or
LZTR1-related SWN.
METHODS: We assessed the variant detection rates for the three major SWN genes (
NF2,
LZTR1 and
SMARCB1) in 154 people, from 150 families, who had at least one non-vestibular schwannoma, but who did not meet clinical criteria for
NF2-related SWN at the time of genetic testing.
RESULTS: We found that 17 (11%) people from 13 families had a germline
SMARCB1 variant and 19 (12%) unrelated individuals had a germline
LZTR1 variant. 19 people had an
NF2 variant, but 18 of these were mosaic and 17 were only detected when 2 tumours were available for testing. The overall detection rate was 25% using blood alone, but increased to 36% when tumour analysis was included. Another 12 people had a germline variant of uncertain significance (VUS).
CONCLUSIONS: There were similar proportions of
LZTR1,
SMARCB1 or mosaic
NF2. However, since an
NF2 variant was detected in tumours from 103 people, it is likely that further cases of mosaicism would be detected if more people had additional tumours available for analysis. In addition, if further evidence becomes available to show that the VUSs are pathogenic, this would significantly increase the proportion of people with a genetic diagnosis. Our results indicate the importance of comprehensive genetic testing and improved variant classification.
AB - BACKGROUND: Most schwannomas are isolated tumours occurring in otherwise healthy people. However, bilateral vestibular schwannomas (BVS) or multiple non-vestibular schwannomas indicate an underlying genetic predisposition. This is most commonly
NF2-related schwannomatosis (SWN), but when BVS are absent, this can also indicate
SMARCB1-related or
LZTR1-related SWN.
METHODS: We assessed the variant detection rates for the three major SWN genes (
NF2,
LZTR1 and
SMARCB1) in 154 people, from 150 families, who had at least one non-vestibular schwannoma, but who did not meet clinical criteria for
NF2-related SWN at the time of genetic testing.
RESULTS: We found that 17 (11%) people from 13 families had a germline
SMARCB1 variant and 19 (12%) unrelated individuals had a germline
LZTR1 variant. 19 people had an
NF2 variant, but 18 of these were mosaic and 17 were only detected when 2 tumours were available for testing. The overall detection rate was 25% using blood alone, but increased to 36% when tumour analysis was included. Another 12 people had a germline variant of uncertain significance (VUS).
CONCLUSIONS: There were similar proportions of
LZTR1,
SMARCB1 or mosaic
NF2. However, since an
NF2 variant was detected in tumours from 103 people, it is likely that further cases of mosaicism would be detected if more people had additional tumours available for analysis. In addition, if further evidence becomes available to show that the VUSs are pathogenic, this would significantly increase the proportion of people with a genetic diagnosis. Our results indicate the importance of comprehensive genetic testing and improved variant classification.
KW - Adult
KW - Female
KW - Genetic Predisposition to Disease
KW - Genetic Testing
KW - Germ-Line Mutation/genetics
KW - Humans
KW - Male
KW - Middle Aged
KW - Neurilemmoma/genetics
KW - Neurofibromatoses/genetics
KW - Neurofibromatosis 2/genetics
KW - Neurofibromin 2/genetics
KW - SMARCB1 Protein/genetics
KW - Skin Neoplasms/genetics
KW - Transcription Factors/genetics
UR - http://www.scopus.com/inward/record.url?scp=85204210542&partnerID=8YFLogxK
U2 - 10.1136/jmg-2024-110217
DO - 10.1136/jmg-2024-110217
M3 - Article
C2 - 39209702
SN - 1468-6244
VL - 61
SP - 1011
EP - 1015
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
IS - 11
ER -